(December 17, 2020, 3:54 PM EST) -- BOSTON — Biotechnology company Biogen Inc. has agreed to pay $22 million to resolve allegations that it violated the False Claims Act by using patient assistance foundations to cover patient co-pays for the company’s multiple sclerosis drugs Avonex and Tysabri, the U.S. Justice Department announced Dec. 17 (United States, et al., ex rel. Paul Nee v. Biogen Inc., et al., No 17-cv-10192, D. Mass.)....